This inventor holds 1 USPTO granted patent. Top assignee: Abelzeta Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Lin Zhu - Innovator in Chimeric Antigen Receptor Technology
Introduction
Lin Zhu is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the development of chimeric antigen receptors (CARs). His work focuses on enhancing the efficacy of engineered T cells for targeted cancer therapies.
Latest Patents
Lin Zhu holds a patent titled "Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof." This patent represents a crucial advancement in the treatment of cancers that express the CD20 antigen, such as certain types of lymphoma and leukemia. The innovation aims to improve the specificity and effectiveness of T cell therapies.
Career Highlights
Lin Zhu is currently employed at Abelzeta Inc., where he continues to push the boundaries of cancer treatment through innovative research. His work has garnered attention in the scientific community, contributing to the growing field of CAR T cell therapy.
Collaborations
Lin collaborates with notable colleagues, including Yihong Yao and Jiaqi Huang. Their combined expertise enhances the research and development efforts at Abelzeta Inc., fostering an environment of innovation and discovery.
Conclusion
Lin Zhu's contributions to the field of immunotherapy through his patent and work at Abelzeta Inc. highlight his role as a key innovator in cancer treatment. His ongoing research promises to advance therapeutic options for patients battling cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile